JP2003512354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512354A5 JP2003512354A5 JP2001531799A JP2001531799A JP2003512354A5 JP 2003512354 A5 JP2003512354 A5 JP 2003512354A5 JP 2001531799 A JP2001531799 A JP 2001531799A JP 2001531799 A JP2001531799 A JP 2001531799A JP 2003512354 A5 JP2003512354 A5 JP 2003512354A5
- Authority
- JP
- Japan
- Prior art keywords
- atorvastatin calcium
- crude
- amorphous atorvastatin
- cooling
- amorphous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims 4
- 229960001770 atorvastatin calcium Drugs 0.000 claims 4
- 238000001816 cooling Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903634 | 1999-10-18 | ||
| HU9903634A HU226640B1 (en) | 1999-10-18 | 1999-10-18 | Process for producing amorphous atorvastatin calcium salt |
| PCT/HU2000/000106 WO2001028999A1 (en) | 1999-10-18 | 2000-10-17 | Process for the preparation of amorphous atorvastatin calcium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512354A JP2003512354A (ja) | 2003-04-02 |
| JP2003512354A5 true JP2003512354A5 (cg-RX-API-DMAC7.html) | 2005-04-21 |
Family
ID=90014241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001531799A Pending JP2003512354A (ja) | 1999-10-18 | 2000-10-17 | 非晶質アトルバスタチンカルシウムの製法 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1235800B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003512354A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100664353B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1157374C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE345327T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU1166301A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2388018C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ300071B6 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60031882T2 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20020334B1 (cg-RX-API-DMAC7.html) |
| HU (1) | HU226640B1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL354604A1 (cg-RX-API-DMAC7.html) |
| RS (1) | RS50473B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2255932C2 (cg-RX-API-DMAC7.html) |
| SK (1) | SK286861B6 (cg-RX-API-DMAC7.html) |
| UA (1) | UA72777C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001028999A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| DE10135493A1 (de) * | 2001-07-20 | 2003-01-30 | Jobst Krauskopf | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
| AU2002255479B2 (en) | 2001-07-30 | 2008-09-11 | Dr. Reddy's Laboratories Ltd. | Crystalline forms VI and VII of atorvastatin clacium |
| HUP0500074A3 (en) * | 2002-03-18 | 2005-07-28 | Biocon Ltd Bangalore | Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| WO2003099785A1 (en) * | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| WO2005092852A1 (en) | 2004-03-17 | 2005-10-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| CN1960972A (zh) * | 2004-04-16 | 2007-05-09 | 辉瑞产品公司 | 用于形成无定形阿托伐它汀钙的方法 |
| CN1692906A (zh) * | 2004-04-30 | 2005-11-09 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
| CA2649054A1 (en) | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
| CA2573969C (en) * | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| WO2006037125A1 (en) | 2004-09-28 | 2006-04-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| CN101039906A (zh) * | 2004-10-18 | 2007-09-19 | 特瓦制药工业有限公司 | 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物 |
| WO2006046109A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| ATE466840T1 (de) | 2005-11-21 | 2010-05-15 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN103274985B (zh) * | 2010-12-03 | 2016-03-09 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| ATE123020T1 (de) * | 1990-05-11 | 1995-06-15 | American Cyanamid Co | N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe. |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| WO1998012200A1 (en) * | 1996-09-20 | 1998-03-26 | Meiji Seika Kaisha Ltd. | A crystalline substance of cefditoren pivoxyl and the production of the same |
-
1999
- 1999-10-18 HU HU9903634A patent/HU226640B1/hu not_active IP Right Cessation
-
2000
- 2000-10-17 KR KR1020027004906A patent/KR100664353B1/ko not_active Expired - Fee Related
- 2000-10-17 WO PCT/HU2000/000106 patent/WO2001028999A1/en not_active Ceased
- 2000-10-17 RU RU2002113564/04A patent/RU2255932C2/ru not_active IP Right Cessation
- 2000-10-17 CZ CZ20021256A patent/CZ300071B6/cs not_active IP Right Cessation
- 2000-10-17 PL PL00354604A patent/PL354604A1/xx not_active Application Discontinuation
- 2000-10-17 AU AU11663/01A patent/AU1166301A/en not_active Abandoned
- 2000-10-17 JP JP2001531799A patent/JP2003512354A/ja active Pending
- 2000-10-17 EP EP00973115A patent/EP1235800B1/en not_active Expired - Lifetime
- 2000-10-17 UA UA2002054059A patent/UA72777C2/uk unknown
- 2000-10-17 DE DE60031882T patent/DE60031882T2/de not_active Expired - Fee Related
- 2000-10-17 CN CNB008144583A patent/CN1157374C/zh not_active Expired - Fee Related
- 2000-10-17 HR HR20020334A patent/HRP20020334B1/xx not_active IP Right Cessation
- 2000-10-17 SK SK519-2002A patent/SK286861B6/sk not_active IP Right Cessation
- 2000-10-17 AT AT00973115T patent/ATE345327T1/de not_active IP Right Cessation
- 2000-10-17 CA CA002388018A patent/CA2388018C/en not_active Expired - Fee Related
- 2000-10-17 RS YUP-283/02A patent/RS50473B/sr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003512354A5 (cg-RX-API-DMAC7.html) | ||
| RU2002113564A (ru) | Способ получения аморфного аторвастатина кальция | |
| DE60109960T2 (de) | 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien | |
| HRP20020334B1 (hr) | Proces za pripremu amorfnog kalcij-atorvastatina | |
| ES2238022T1 (es) | Polimorfos de valsartan. | |
| PT2251330E (pt) | 4-hidroxibenzomorfanos | |
| ES2196803T3 (es) | Procedimiento en fase acuosa para fabricar dispersiones solidas de paroxetina. | |
| NO20011272L (no) | Fremgangsmåte for fremstilling av ren citalopram | |
| NO20011271A (no) | Fremgangsmåte for fremstilling av ren citalopram | |
| IS7308A (is) | Nýr sertralínhýdróklóríðfjölgervingur og efnablanda sem inniheldur hann, nýjar aðferðir til að framleiða sertralínhýdróklóríðfjölgervinga og myndlausform | |
| ID25950A (id) | Katalis-katalis untuk memproduksi aldehid tidak jenuh dan asam karboksilat tidak jenuh dan proses untuk produksi aldehid tidak jenuh dan asam karboksilat tidak jenuh menggunakan katalis | |
| Feng et al. | Synthesis of polysubstituted pyridines under combined microwave and ultrasound irradiation: K2CO3-promoted tandem addition/cyclization/hydrogen shift process | |
| BR0109507A (pt) | Processo para preparação de forma i, cristalina, de carbegolina | |
| MXPA02011524A (es) | Nuevas formas de cuerpo solido de mesoprogestina, 11b-[4e-(hidroxiiminometil)-fenil]-17alfa-metoximetil-17- ??-metoxi-estra-4,9-dien-3-ona. | |
| EP1395562A4 (en) | 5-CHLORO-3- (4-METHANSULFONYL PHENYL) -6 - METHYLC2,3-] BIPYRIDINYL IN PURE CRYSTALLINE FORM AND SYNTHESIS METHOD | |
| PT88301B (pt) | Processo para a preparacao de derivados de oxima de 1,2,5,6-tetraidropiridina e de composicoes farmaceuticas que os contem | |
| ES2311034T3 (es) | Derivados de indol y uso de los mismos en medicamentos. | |
| JP2002338382A5 (cg-RX-API-DMAC7.html) | ||
| ATE276986T1 (de) | Verfahren zur herstellung von tetrahydrofuran | |
| JP2003529555A5 (cg-RX-API-DMAC7.html) | ||
| Cavé et al. | Methyl methacrylate as acceptor in the asymmetric Michael reaction using chiral β-enaminoesters: Simultaneous, complete stereocontrol of a quaternary carbon center and a tertiary one in the β-position | |
| NO20014777D0 (no) | Fremgangsmåte for behandling av flyveaske under anvendelse av saltsyre | |
| DE69208797D1 (de) | Verfahren zur Synthese von Succinylobernsternsäuredialkylestern und ihre Umwandlung in Dialkyl 2,5-Diarylamino-3,6-Dihydroterephthalsäureester | |
| JP2003241418A5 (cg-RX-API-DMAC7.html) | ||
| JPH05213934A (ja) | ピラゾール誘導体 |